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ABSTRACT 
The process of inflammation is important for both normal health and in a number 
of diseases, such as metabolic disorders, autoimmune diseases, and 
neurodegenerative diseases. Mitochondria are vital for the functioning of all cells. 
It had been implicated as a key player in inflammatory processes, especially 
through reactive oxygen species as signals of various immune responses. This 
study aimed to establish a THP-1 cell line with compromised mitochondrial 
functions, using antimycin A as a Complex III inhibitor, and to investigate the 
role of mitochondrial stress, as monitored by the expression of Hsp60, in 
inflammatory processes. 
 
High concentrations of antimycin A (100 and 200 µM) were cytotoxic to THP-1 
monocytes that they were rapidly killed within 48 hours of exposure. Lower 
concentrations of antimycin A (5, 10, 25 and 50 µM) gave growth inhibition 
effects to THP-1 monocytes. Pyruvate and uridine were used with an intention of 
rescuing the THP-1 cell growth at lower antimycin A concentrations. The THP-1 
monocytes treated with antimycin A with uridine and pyruvate showed more 
growth compared to the ones without uridine and pyruvate supplement. Yet this 
difference is insignificant statistically. The expressions of Hsp60 and TNF-α at 
the mRNA level was monitored using reverse transcriptase polymerase chain 
reaction. Hsp60 expression from THP-1 monocytes only showed some minor 
fluctuations in different antimycin A concentrations, regardless of uridine and 
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pyruvate supplement, indicating the stress mitochondrial response was unobvious. 
On the other hand, TNF-α expression was dramatically down-regulated in THP-1 
monocytes treated with antimycin A only compared to the untreated control and 
ones supplemented with uridine and pyruvate. These results suggest that 
antimycin A may have inhibition effect towards TNF-α expression, and uridine 
and pyruvate could also have other functions in THP-1 monocytes apart from 
redox rescue compounds. Yet the mitochondrial stress response shown by Hsp60 
induction still remains to be further investigated.  
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Inflammatory Response 
Inflammation response is broadly specific, induced by infection or cell damage. It 
also responds to cytokines released by cells of adaptive immune response. The 
classic signs of inflammation are vasodilation (redness and heat), swelling and 
pain. Vasodilation is caused by increased diameter of local blood vessels, 
allowing increased blood flow to affected areas. Swelling is because of increased 
adhesion of leukocytes to local blood vessel walls and enhanced capillary 
permeability, encouraging influx of leukocytes. The pain is due to both swelling 
and the stimulation of pain receptor in skin mediated by peptide bradykinin (Mak 
& Saunders, 2006). 
 
Damaged tissue or cells release chemotactic molecules such as C5a, attracting 
macrophages and neutrophils, the main leukocytes involved in inflammation. 
These leukocytes push through blood vessels entering damaged sites. The 
concentration gradients of chemotactic molecules (i.e. chemotaxis) are required 
for subsequent cell migration. 
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The initiation of inflammation is not well understood. It is possibly triggered by 
proteins released from damaged tissue due to infection or injury. Mediators like 
proinflammatory cytokines, TNF-α and IL-6 are secreted by macrophages to 
activate down-stream inflammatory responses. TNF-α and IL-6 are sent by 
activated macrophages to hepatocytes in the liver, which respond with the 
systematic production of acute-phase proteins. These proteins bind to a wide 
range of bacterial agents, thereby eliminating pathogens or “antigens” in a less 
specific way. 
 
A number of innate immune cells have pattern recognition molecules on their cell 
surfaces as binding receptors of antigens. Series of signal transduction pathways 
can be activated after antigens bind to these receptors. Examples of these pattern 
recognition molecules on the cell surfaces of monocytes and macrophages include 
cluster of differentiation 14 (CD14), toll-like receptors 2 and -4 (TLR2 and TLR4). 
The signal cascades then stimulate other nuclear transcription factors for more 
inflammatory responses or stimulating adaptive immune responses. Inflammation 
is therefore an important bridge between innate and adaptive immune responses 
(Mak &Saunders, 2006). 
 
Impaired inflammation is related to deleterious consequences of many pathologies, 
including neurodegeneration to central nervous system such as Alzheimer’s 
disease, Parkinson’s disease and multiple sclerosis (Centonze et al., 2007; Esiri, 
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2007), and autoimmune diseases due to antigen from one’s own body. Some 
examples of autoimmune diseases likely to be associated with inflammation are 
Type One Diabetes Mellitus (T1DM), Kawasaki’s disease, Sjorgen’s disease and 
rheumatoid arthritis. 
 
1.2 Mitochondria and Oxidative Phosphorylation 
Mitochondria are sites of oxidative phosphorylation, citric acid cycle and β-
oxidation of free fatty acids (Bailey et al., 2005). ROS are produced in Complex I 
(NADH / ubiquinone oxidoreductase) and III (ubiquinol / cytochrome c oxido-
reductase) of electron transport system (ETS) (Fleury et al., 2002). The major 
ROS generated, superoxide anion (O2
-
), hydrogen peroxide (H2O2) and hydroxyl 
radical (OH
∙
), are by-products from ETS and are also stimuli for apoptosis (Fleury 
et al., 2002). O2 is converted to O2
-
 because of a single electron leakage from one 
of the mitochondrial complexes. O2
-
 is then converted into H2O2 with the 
catalysing effect of superoxide dismutase. H2O2 is further changed into OH
∙
 in 
presence of Fe
2+
. Despite these ROS produced during oxidative phosphorylation, 
natural antioxidants such as superoxide dismutase, glutathione reductase and 
glutathione peroxidase are present in mitochondria (Fleury et al., 2002). Another 
important mitochondrial protein associated with increased ROS production is 
uncoupling protein-2 (UCP2). UCP2 diminishes mitochondrial ROS production 
by lowering the mitochondrial membrane potential (Arsenijevic et al., 2000), and 
is up-regulated in response to increased ROS in macrophages (Giardina et al., 
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2008). In some circumstances however, ROS generated overwhelm the protection 
effect of antioxidants. This phenomenon is termed oxidative stress. 
 
Mitochondrial oxidative stress is known as an important factor in ageing, which 
can induce intrinsic apoptosis to drive tissue ageing (Sastre et al., 2003). ROS 
have the potential to damage proteins, lipids and DNA (Halliwell, 1992, 2001). 
Oxidative stress-mediated mitochondrial impairment and/or dysfunction are 
increasingly believed to play key roles in many diseases including arthritis (Vaille 
et al., 1990), ischemic diseases (Omar &  McCord, 1991), Alzheimer’s disease, 
Parkinson’s disease (Mattson & Kroemer, 2003; Reddy & Beal, 2005), and many 
others. 
 
1.2.1 Role of ROS in the Immune System 
Yet apart from causing damages, ROS is also adapted by the immune system in 
higher organisms as defense mechanisms and to initiate further responses. 
Neutrophils and macrophages produce superoxide radical with NADPH oxidase 
to fight with invading pathogens (McCord, 2000). In addition, superoxide is a 
mediator of inflammation. Superoxide and hydrogen peroxide can activate kinase 
signaling cascades, including protein kinase C (Klann et al., 1998), mitogen-
activated protein kinase (MAPK) and transcription factors (Droge, 2002). Chronic 
oxidative stress subsequently causes the activation of transcription factors, NF-κB 
and AP-1, followed by the induction of other genes producing pro-inflammatory 
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cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1 and -6 (IL-1 and 
IL-6) and other downstream inflammatory responses (Tse et al., 2004). 
Inflammation is increasingly being recognised as a cause of major metabolic and 
neurodegenerative diseases, including Type 2 Diabetes (T2D), atherosclerosis, 
Alzheimer’s Disease, Parkinson’s Disease and dementia (Bozner et al., 2002; 
Tytell & Hooper, 2001). Since ROS are critical to the immune system and many 
aetiologies, catalytic antioxidants were seen as a potential drug target for 
inflammatory diseases. Catalytic antioxidants applied to lipopolysaccharide-
induced macrophages suppressed proinflammatory cytokine and ROS production 
via inhibition of NF-κB DNA binding, without affecting MAPK signalling 
pathway. Catalytic antioxidants were thus claimed by the authors as protection in 
chronic inflammatory diseases (Tse et al., 2004).  
 
1.3 Stress Proteins – The Counteracting Molecules in 
Mitochondria for Cellular Stress 
An early counteracting activity of oxidative stress inside mitochondria is the up-
regulation of heat shock proteins (Hsps) or chaperones, a class of mitochondrial 
stress protein that is one of the members of heat shock protein family, to protect 
other macromolecules. Hsps were discovered by Ferrucio Ritossa and co-workers 
in 1962: heat shock induced puffing patterns in the polytene chromosomes of 
salivary glands in Drosophila melanogaster larva (Ritossa, 1962). Hsp genes were 
latter identified in 1974 so introduced the term “heat shock proteins” (Tissieres et 
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al., 1974). Hsp gene sequences are highly conserved and present in prokaryotes 
and eukaryotes (Pockley, 2003), which are named based on molecular weights. 
The Hsp that this study focused on is Hsp60 with its molecular weight as 60kDa. 
Hsp60 is the eukaryotic homologue of bacterial GroEL protein, which is located 
in the matrix of mitochondria (Randord et al., 2000). Hsp10 is the co-chaperone 
of Hsp60. These two Hsps form a complex that function in co-operation. In 
eukaryotes, the protein is encoded in the nuclear DNA, synthesised in the cyctosol 
then imported into the mitochondria. It assists proper folding of newly synthesised 
polypeptides, facilitating protein transport through membrane channels, 
preventing aggregation and denaturation of proteins under heat shock, as well as 
refolding the denatured proteins back into their naïve structures (Hartl, 1996). 
Hsp60 is thus vital for maintaining cellular homeostasis and tolerance to stresses. 
 
Moreover, hsp60, Hsp70 and Hsp90, both alone and in combination, protect 
against intracellular β-amyloid stress. The Complex IV inhibition effect of β-
amyloid was neutralised by Hsp60 (Veereshwarayya et al., 2006). Plus Hsp60 and 
Hsp10 in combination or individually protect mitochondrial integrity and 
oxidative phosphorylation capacity during ischemia/reperfusion injury in cardiac 
myocytes (Lin et al., 2001). 
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1.3.1 Role of Hsp60 in the Immune Response 
It was thought that eukaryotic Hsp60 is only located in the mitochondria, however, 
recent evidence indicate that this protein is expressed on the plasma membranes of 
cells and indeed secreted from cells under stress conditions (Maguire et al., 
2002a). Immunoprecipitation studies showed that hsp60 is also located on the cell 
surface (Gupta & Austin, 1987). Apart from its chaperonin function, Hsp60 is also 
antiapoptotic by forming macromolecular complexes with bak and bax to block 
the release of cytochrome c and the subsequent caspase (Kirchhoff et al., 2002).  
 
The role of Hsp60 played in immune response was not realised until Hsp60 was 
discovered to have a dual function of chaperonin and signalling (Maguire et al., 
2002b). Extracellular, bacterial hsp60 are detected by the receptor on 
macrophages. The detection then activated the signalling pathway to nucleus, 
switching on transcription factor NF-κB, thereby producing inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, and IL-8 (Lewthwaite et al., 2007). Also 
bacterial Hsp60 was discovered to act as an antigen to T-cells, despite their 
sequence homology to human Hsp60 (Schwartz & Cohen, 2000). Many studies 
confirmed that both human and bacterial Hsp60, if present at the cell surface of 
immune cells, are links between innate and adaptive immune responses. When 
detected by the cell surface receptors such as CD14, TLR-2 and TLR-4, they are 
seen as antigens by human monocytes, macrophages and dendritic cells, as well as 
ligands for antigen receptors in T-cells and B-cells ((Zhao et al., 2007), reviewed 
in (Praeres da Costa et al., 2003; Zhao et al., 2007)). The follow-on effect of this 
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is the activation of serine/threonine kinase cascade involving mitogen-activated 
protein kinases (MAPK), p38, janus-kinase (JNK) and extracellular signal-
regulated kinases (ERK), switching on the transcription factors AP-1 and NF-κB 
in the nucleus, thereby producing pro-inflammatory cytokines and other 
inflammatory responses (Lewthwaite et al., 2007; Wallin et al., 2002; Zanin-
Zhorov et al., 2005). Mammalian Hsp60 acts as a target antigen in Type 1 
Diabetic (T1D) mice (Elias et al., 1991). Hsp60 is therefore a danger signal in the 
immune system (Chen et al., 1999). 
 
The signaling pathways of extracellular Hsps (cpn60, -70 and gp 96) in 
monocytes, macrophages and dendritic cells had been elucidated as many studies 
focused on adding extracellular Hsp60 to immune cells and observing the effects. 
However, relatively little had been done on the secretion of Hsp60 from the 
mitochondria. Two recent studies had shown that the intracellular secretion of 
Hsp60 and -70 in cardiac muscles are likely to be via attaching to the membrane 
of exosomes, a type of intracellular vesicle likely to contain lipid rafts (Lancaster 
& Febbraio, 2005; Gupta & Knowlton, 2007). Yet no such work had been done on 
monocytes and macrophages or the effect of intracellular Hsp60 on the MAPK 
cascade due to mitochondrial dysfunction in these cells. 
 
9 
 
1.4 Cell Culture Model Systems for Studying Mitochondrial 
Dysfunction 
A special type of cell line called rho zero cells (ρº) are very useful to study 
follow-on consequences of compromised mitochondrial functions. ρº cells have 
their mitochondrial DNA depleted by a mitochondrial DNA inhibitor, usually 
ethidium bromide (Nagley et al., 1977). This means that their oxidative 
phosphorylation is dysfunctioned, so they rely on extensive glycolysis to generate 
cellular energy in the form of ATP. Many kinds of eukaryotic cells have been 
generated to become ρº. Examples include human Namalwa cells, a human B-type 
lymphoblastoid cell line (Larm et al., 1994; Martinus et al., 1993); HL-60, human 
promyelocytic leukemia cell line (Gómez-Díaz et al., 1997); rat hepatoma cells, 
H4 (Martinus et al., 1996) and human neuroblastoma cells, SH-SY5Y (Hyun et al., 
2007). Alternatively cells with fully functioning mitochondria grown in prolonged 
anaerobic conditions can also be used to study mitochondrial dysfunction 
(Vaillant et al., 1991). 
 
1.4.1 Maintenance of Cells Having Compromised Mitochondrial Functions 
NAD
+
 is converted to NADH during glycolysis. In normal oxidative 
phosphorylation, the resulting NADH is reoxidised to NAD
+
. Yet this pathway 
will not provide adequate NAD
+
 if the electron transport system (ETS) is partially 
or totally inavailable. Alternatively pyruvate can be converted to lactate as a route 
of NAD
+
 production. For this reason extra pyruvate was added to cells relying 
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heavily on glycolysis for energy production (Guidarelli et al., 2006; King & 
Attardi, 1989). Thus pyruvate can be called the “redox sink molecule” or “redox 
rescuer” for this kind of function. 
 
Another pathway for ρº cells to generate enough NAD+ is through the activity of 
plasma membrane redox system, consisting of a series of molecules transferring 
electrons from internal reductants such as NAD(P)H to external oxidants, thereby 
protecting cells against external oxidative stress (Alcain et al., 1991; del Castillo-
Olivares et al., 2000). A key molecule in the plasma membrane redox system is 
Coenzyme Q10, which protects lipids from oxidative stress in its reduced form. 
Coenzyme Q10 donates electrons to α-tocopherol radical and ascorbate free radical, 
therefore maintaining the reduced form of α-tocopherol and ascorbate that they 
can continuously scavenge free radicals (Kagan et al., 1990a, b). Indeed, Martinus 
et al., 1993 reported that ρº human Namalwa cells could be sustained by 
Coenzyme Q10 supplement. Martinus et al., 1993 also demonstrated that 
ferrycyanide, an anion impermeant to plasma membrane, could enhance ρº cell 
growth, possibly by acting as an extracellular electron acceptor, allowing the 
plasma membrane oxidase to reoxidise cytosolic NADH to NAD
+
, thereby 
supplying more NAD
+
 for glycolysis. Soon after then, it was discovered that the 
up-regulation of plasma membrane oxidoreductase activity is vital for human 
Namalwa ρº cells to survive. Inhibiting one of the enzymes from plasma 
membrane redox system, NADH-ferricyanide reductase with pCMBS caused 
rapid decease of the ρº cells (Larm et al., 1994). 
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Another blockage due to the malfunction of ETS is the pyrimidine biosynthetic 
pathway. The key enzyme involved in pyrimidine biosynthesis, dihydroorotate 
dehydrogenase complex, is coupled to the mitochondrial ETS (Jones, 1980). 
Uridine was therefore used to bypass this obstacle (Morais et al., 1980). 
 
1.5 Types of Mitochondrial Inhibitors 
Some examples of well-known mitochondrial inhibitors with their target and 
mode of actions are briefly summarised in this section, with a particular emphasis 
on antimycin A. Ethidium bromide is one of the intercalating agents with aromatic 
macrocycles composed of fused, heterocyclic rings, which inserts between DNA 
base pairs. The base pairs are forced apart to accommodate the intercalating agent. 
If too many inserted, it causes the double helix to unwind. Through this way 
ethidium bromide acts as a mitochondrial DNA inhibitor (Garret & Grisham, 
2005). Rotenone, a mitochondrial Complex I inhibitor, prevents the electron 
transfer from iron-sulfur centres in Complex I to ubiquinone, the reaction 
catalysed by NADH-ubiquinone reductase. Oligomycin, an ATP Synthase 
inhibitor, binds to a subunit of F0, and blocks the movement of protons through F0 
(Garret & Grisham, 2005). 
 
Antimycin A was first identified by Leben and Keitt as a fungicide produced by 
Streptomyces, with its mitochondrial inhibitory effect firstly observed by Ahmad 
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and co-workers (Slater, 1973). Antimycin A is an electron transport Complex III 
inhibitor. It inhibits Coenzyme Q-cytochrome c reductase by blocking electron 
transfer between bH and Coenzyme Q in the Qn site (Garret & Grisham, 2005). It 
also causes a single electron leakage to oxygen that is supposed to go from the 
mobile head domain of Rieske iron-sulfur protein to cytochrome c1 subunit (Nohl 
et al., 2003). 
1.6 Use of Immune Cells in Cell Culture Model Systems 
Model systems of human immune cell culture are useful to study complicated 
reactions of immune response, since one can do limited experimental assays with 
live humans due to human ethics. Cell lines that behave similarly compared to 
native cells in human body, together with the ability to differentiate into other 
immune cell types after chemical inductions, become preferential options for such 
model systems. In addition, it is even better if the chosen cell types are able to 
proliferate but not to self-differentiate into tissue cell types after certain number of 
cycles. Because human leukemia cell lines satisfy all the above conditions, they 
therefore are successful candidates of immune cell culture model systems. 
Examples of commonly used human leukemia cell lines include promyelocytic 
leukemia cell line HL-60 (Thompson et al., 1988) and acute leukemia monocyte 
THP-1 (Guidarelli et al., 2006; Zhuang et al., 1998). As HL60 can be induced into 
monocytes using 1α,25-dihydroxyvitamin D3, (Mills et al., 1999) and THP-1 
monocytes are able to differentiate into macrophages after the induction of 
phorbol myristic acetate (Auwerx, 1991), combined with their ability to produce 
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proinflammatory cytokines such as TNF-α, they are used extensively to study 
inflammatory and associated responses. 
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1.6 Outline of this Study 
This study intended to establish a cell culture model system with compromised 
mitochondrial functions to study the relationship between inflammatory response 
and mitochondrial dysfunction. The experimental set-up is divided into four parts: 
 
1. Establishing THP-1 monocytes with compromised mitochondrial functions 
using antimycin A; 
 
2. Investigating the effect of redox rescue of antimycin A-treated monocytes 
with pyruvate and uridine to establish a long term culture of mitochondrial 
compromised cells; 
 
3. Confirming the influence of mitochondrial stress by monitoring the 
expression of Hsp60 at the mRNA level; 
 
4. Investigating the inflammatory response from THP-1 monocytes 
undergoing mitochondrial inhibition by monitoring the expression of TNF-
α at the mRNA level. 
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CHAPTER TWO MATERIALS 
AND METHOD 
2.1 Materials 
2.1.1 Laboratory chemicals and reagents 
All chemicals and reagents used in this project are listed in Table 1 together with their 
sources. 
Table 1: Chemicals and reagents 
Chemical or Reagent Source 
3-(N-morpholino) propanesulfonic acid (MOPS) AppliChem 
Agarose AppliChem 
Antimycin A Sigma 
Boric Acid Ajax Finechem 
Deionised formamide Sigma 
Diethyl pyricarbonate (DEPC) Sigma 
DNase treatment kit Invitrogen 
Ethidium bromide Sigma 
Ethylenediaminetetra-acetic acid (EDTA) BDH Laboratory 
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Supplies 
Fetal bovine serum Invitrogen 
Gel loading dye Ficoll 
N-2-Hydroxyethylpiperazine-N-2-ethanesulphonic acid 
(HEPES) 
BDH Laboratory 
Supplies 
RPMI liquid growth medium Invitrogen 
RT-PCR kit Invitrogen 
Sodium acetate Ajax Chemicals 
Sodium pyruvate Sigma 
Streptomycin/penicillin 
Ruakura Research 
Institute 
Tris AppliChem 
TRIzol Reagent Invitrogen 
Uridine Sigma 
    
 
2.1.2 Stock Solutions 
Stock solutions were routinely made in the laboratory. The compositions of these are 
listed in Table 2: 
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Table 2: Stock solutions 
Solution Composition 
10X gel loading dye 
0.75 g Ficoll, 6.25 mg Bromophenol blue, 0.5 mL 10X SB 
buffer, 4 mL sH2O 
10X MOPS buffer (pH 
7) 83.7 g MOPS, 8.2 g sodium acetate, 2.9 g EDTA in 1 L sH2O 
10X SB buffer (pH 8.5) 28 g boric acid, 4.5 g sodium hydroxide in 1 L sH2O 
10X TBE buffer 
108 g Tris, 55 g boric acid, 9.5 g EDTA in 1 L 0.01% DEPC 
water 
Antimycin A Powder in 95% ethanol (10 mM) 
Ethanol 100% ethanol diluted with sH2O (95%) 
HEPES Powder in sH2O (0.25 mM) 
Sodium pyruvate Powder in sH2O (100 mM) 
Streptomycin/penicillin Powder in sH2O (5 mM) 
TE buffer (pH 8.0) 10 mM Tris-HCl, 1 mM EDTA in 1 L 0.01% DEPC water 
Uridine Powder in sH2O (20 mM) 
    
 
2.1.3 Standard Growth Medium for THP-1 Cells 
The liquid growth medium was routinely made in the laboratory containing the 
materials listed in Table 3: 
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Table 3: Components of THP-1 growth medium 
Chemical or Reagent 
0.25 mM HEPES 
1 mM Sodium pyruvate 
10% Fetal Bovaine Serum 
1X RPMI liquid medium 
50 μM Streptomycin/penicillin 
  
 
The medium was filter sterilised with a 0.22 μM syringe filter (Sartorious Minisart®) 
and stored at 4°C, except being pre-incubated at 37°C for 30 min prior to use. 
 
2.1.4 cDNA Synthesis with Reverse Transcriptase 
The cDNA template was synthesised using components purchased from Roche. 
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Table 4: cDNA synthesis materials 
Material Name Content 
Transciptor Reverse Transcriptase 25 U/μL 
(Enzyme) 200 mM potassium phosphate 
 
2 mM dithiothreitol (DTT) 
 
0.2% (v/v) Triton X-100 
 
50% (v/v) Glycerol (pH 7.2) 
  5X RT Reaction Buffer 250 mM Tris-HCl 
 
150 mM KCl 
 
40 mM MgCl2 (pH 8.5) 
  Protector RNase Inhibitor 40 U/μL 
 
20 mM HEPES-KOH 
 
50 mM KCl 
 
8 mM DTT 
 
50% glycerol (pH 7.6) 
  Anchored-Oligo(dT) 18 Primer 50 μM 
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Random Hexamer Primer 600 μM 
  Control RNA 50 ng/μL 
 
Stabilised solution with a total RNA 
fraction purified from K562 cell line 
  Control Primer Mix PBGD 5 μM forward and reverse primer 
 
Porphobilinogen deaminase (pH 8.3) 
  PCR Grade Water Nuclease-free water 
    
 
2.1.5 Polymerase Chain Reaction (PCR) 
Polymerase chain reactions were performed with FastStart Taq Polymerase (Roche) 
and other materials purchased mostly from Roche. 
Table 5: PCR Materials 
Material Name Content 
FastStart Taq DNA Polymerase 5 U/μL 
(Enzyme) Storage buffer: 20 mM Tris-HCl (pH 9) 
 
100 mM KCl 
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0.1 mM EDTA 
 
1 mM DTT 
 
0.2% (v/v) Tween 20 
 
50% (v/v) Glycerol 
  10X PCR Reaction Buffer 500 mM Tris-HCl 
with 20 mM MgCl2 (pH 8.3) 100 mM KCl 
 
50 mM (NH4)2SO4 
  DNA Ladder (Invitrogen) 10 mM Tris-HCl (pH 7.5) 
 
1 mM EDTA 
   
 
The human GAPDH primer sequences were: 
Forward: ACC ACA GTC CAT GCC ATC AC 
Reverse: TCC ACC ACC CTG TTG CTG TA 
Expected product size: 451 bp 
The human Hsp60 primer sequences were: 
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Forward: TTC GAT GCA TTC CAG CT TG 
Reverse: TTG GGC TTC CTG TCA CAG TT 
Expected product size: 439 bp 
The human TNF-α primer sequences were: 
Forward: CAG AGG GAA GAG TTC CCC AG 
Reverse: CCT TGG TCT GGT AGG AGA CG 
Expected product size: 324 bp 
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2.2 Method 
2.2.1 Cell Culture maintenance 
The human acute monocytic leukaemia cell line, THP-1, was obtained from the 
University of Auckland. The cells were suspended in 10 cm
3
 of the growth medium. 
The cultures were stored in a sterile flask with a filter cap (Nunclon
TM
 Δ Surface) and 
incubated in a sterile incubator at 37°C with 5% CO2. The medium was changed 
every 10 days by centrifuging the cells at 389 rcf for 10 min (Heraeus Megafuge 1.0). 
After that the cells were re-suspended in the new growth medium. Cells were mixed 
with 0.4% tryphan blue stain (Sigma) in a 1:1 ratio, loaded on a haemocytometer then 
counted under a light microscope (Nikon Eclipse TS-100). 
 
2.2.2 Mitochondrial Inhibition Assay 
2.2.2.1 Mitochondrial Inhibition with Antimycin A 
Antimycin A binds to the quinone reduction site of the cytochrome bc1 complex, 
which is part of Complex III of the electron transport system (ETS) (Huang et al., 
2005; Reed et al., 1978; Slater, 1973). Increase and leakage of superoxide radicals 
were also found in rat liver mitochondria treated with antimycin A (Piskemik et al., 
2008). Antimycin A is widely used as an inducer to study mitochondrial oxidative 
stress (Firth et al., 2008; Zhuang et al., 1998). In this experiment antimycin A was 
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dissolved in ethanol due to its insolubility in water. In a 24-well plate, 2 mL of assay 
mixtures were set up with the components listed in Table 6: 
 
Table 6: Composition of cell culture models for mitochondrial inhibition assay 
Chemical or Reagent Concentration 
THP-1 cell culture in RPMI 
medium 
1.84×10
4
 cells/mL 
Antimycin A 5, 10, 25, 50, 100 or 200 μM respectively 
Ethanol (solvent control) Equivalent concentrations as antimycin A 
respectively 
RPMI liquid medium Make up to 2 mL 
    
 
THP-1 cells grown in normal RPMI medium without any additives were used as 
untreated controls. Since antimycin A is soluble in ethanol, a growth study with 
equivalent concentrations (5, 10, 25, 50, 100 or 200 μM respectively) of ethanol 
without any mitochondrial inhibitors was carried out to determine the effect of 
ethanol towards THP-1 cell growth. These THP-1 cells grown in the presence of 
ethanol plus normal medium were used as solvent controls. All concentrations 
including the solvent and untreated controls were done in triplicates. The viable cell 
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numbers of all replicates were counted daily in a haemocytometer by tryphan blue 
stain exclusion. The media were changed on alternative days to avoid the 
accumulation of lactic acid. Pyruvate was converted to lactate to generate NAD
+
 for 
glycolysis, when oxidative phosphorylation was impaired so could not re-generate 
enough NAD
+
 from NADH. The average cell numbers and standard deviations for 
each antimycin A concentration were calculated based on the triplicates. 
 
2.2.2.2 Mitochondrial Inhibition using Antimycin A, Supplemented with Uridine 
and Pyruvate 
This experiment was repeated with 50 μg/mL uridine and 1 mM sodium pyruvate as 
pyrimidine biosynthesis intermediates and redox rescuers (or redox sink molecules), 
together with other components in 2 mL of assay mixtures. The media were also 
changed on alternative days to avoid accumulation of acidic waste products. The 
average cell numbers and standard deviations for each triplicate were calculated. 
 
2.2.3 Antimycin A Dose-Response Assays for Assessing Hsp60 and TNF-α 
Expressions 
2.2.3.1 Attempt One 
In 24-well plates, 2 mL of assay mixtures were set up as shown in Table 4. The initial 
THP-1 cell concentration was 1.84×10
4
 cells/mL. The final concentrations of 
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antimycin A were 5, 10, 25, 50, 100 and 200 μM respectively, with each 
concentration in triplicates. A separate set of the same concentrations (5, 10, 25, 50, 
100 and 200 μM) of antimycin A were set up containing uridine and sodium pyuvate 
as descried in 2.2.2.2. The final concentrations of uridine and sodium pyruvate were 
still 50 μg/mL and 1 mM respectively. The THP-1 cells were exposed to five days of 
different antimycin A concentrations, with media changed every 48 hours. The cells 
were pelleted on Day 4 at 2,000 × g for 7 min, and total RNA extracted (section 
2.2.4.3) immediately after cell harvest. 
 
2.2.3.2 Attempt Two 
The same protocol as 2.2.3.1 was repeated. THP-1 cells were also treated with 
various antimycin A concentrations for five days. Yet the THP-1 cell concentration 
used this time was 1×10
5
 cells/mL. The final antimycin A concentrations in wells 
were 5, 10, 25, 50 μM, plus an untreated control. The same antimycin A 
concentrations were used for uridine and sodium pyruvate treatment. An untreated 
control containing 50 μg/mL of uridine and 1 mM of sodium pytuvate was included. 
100 and 200 μM of antimycin A were unnecessary since most of the THP-1 cells 
were killed within 48 hours under the exposure of such high concentrations of 
mitochondrial inhibitor, so not enough total RNA could be extracted. 
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2.2.4 TRIzol RNA Extraction 
A series of trials for total RNA extraction and Reverse-Transcriptase Polymerase 
Chain Reactions (RT-PCR) were done to ensure that the reagents functioned properly 
and to optimise the protocols. 
 
2.2.4.1 TRIzol RNA Extraction – Attempt One 
1 mL of THP-1 cells (~2×10
5
 cells/mL) was centrifuged (Centrifuge 5415 R, 
Eppendorf) at 13,000 rpm for 3 min. The cell pellets were resuspended in 500 μL 
TRIzol (Invitrogen) and incubated at 15-30°C for 5 min. 100 μL of chloroform was 
added, shaken vigorously by hand for 15 seconds and incubated at 15-30°C for 3 min. 
The mixture was centrifuged (Centrifuge 5415 R, Eppendorf) at 12,000 rpm for 15 
minutes at 4°C. The upper colourless RNA layer was transferred to a new RNase-free 
tube. 250 μL of isopropanol was added to the RNA solution, incubated at 15-30°C for 
10 min then centrifuged (Centrifuge 5415 R, Eppendorf) at 12,000 rpm for 10 min at 
4°C. The RNA pellet was washed with 1 mL of 75% ethanol made with 0.01% DEPC 
(Sigma)-treated water, mixed well by vortex and centrifuged (Centrifuge 5415 R, 
Eppendorf) at 7,400 rpm for 5 min at 4°C. The supernatant was discarded. The RNA 
pellet was air dried on ice for 5-10 min. The pellet was resuspended in 30 μL of 1X 
TE buffer made with 0.01% DEPC-treated water (0.01 % DEPC water) (pH 8.0) and 
kept on ice. The purity of the extracted RNA was quantified with Nanodrop ND-1000 
spectrophotometer. The remaining RNA sample was stored at −80°C. 
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2.2.4.2 TRIzol RNA Extraction – Attempt Two 
500 μL of THP-1 cells (~2×105 cells/mL), instead of 1 mL, were centrifuged 
(Centrifuge 5415 R, Eppendorf) at 2000 × g for 7 min to maximise the TRIzol 
activity. The cell pellets were resuspend in 500 μL TRIzol and incubated at 15-30°C 
for 5 min. 100 μL of chloroform was added, shaken vigorously by hand for 15 sec 
and incubated at 15-30°C for 3 min. The mixture was centrifuged (Centrifuge 5415 R, 
Eppendorf) at 12,000 × g for 15 min at 4°C. The upper colourless RNA layer was 
transferred to a new RNase-free tube. 250 μL of isopropanol was added to precipitate 
the RNA. The content was incubated at 15-30°C for 10 min and at −20°C for 20 min. 
This was then centrifuged (Centrifuge 5415 R, Eppendorf) at 12,000 × g for 10 min at 
4°C. The supernatant was removed. The RNA pellet was washed with 1 mL of 75% 
ethanol made with 0.01% DEPC water, mixed thoroughly by vortex and, centrifuged 
(Centrifuge 5415 R, Eppendorf) at 7,400 × g for 5 min at 4°C. The supernatant was 
discarded. The RNA pellet was air dried for 5-10 min at room temperature inside a 
fume cupboard and resuspended in 20 μL of 1X TE buffer (pH 8.0). The purity of the 
RNA extracted was quantified with Nanodrop ND-1000 spectrophotometer. The 
remaining RNA sample was stored at −80°C. 
 
29 
 
2.2.4.3 TRIzol RNA Extraction – Antimycin A Dose-Response Assays (1) 
Each triplicate, containing 1 mL of THP-1 cells (~5×10
4
 cells/mL per well) from the 
24-well plate were centrifuged (Centrifuge 5415 R, Eppendorf) at 2000 × g for 7 min. 
The cell pellets were resuspend in 500 μL TRIzol and incubated at 15-30°C for 5 min. 
100 μL of chloroform was added, shaken vigorously by hand for 15 sec and incubated 
at 15-30°C for 3 min. The mixture was centrifuged (Centrifuge 5415 R, Eppendorf) at 
12,000 × g for 15 min at 4°C. The upper colourless RNA layer was transferred to a 
new RNase-free tube, with the triplicates from the same antimycin A concentration 
combined into one RNase-free tube. 500 μL of isopropanol was added to precipitate 
the RNA. The content was incubated at 15-30°C for 10 min and at −20°C for 20 min. 
This was then centrifuged (Centrifuge 5415 R, Eppendorf) at 12,000 × g for 10 min at 
4°C. The supernatant was carefully removed. The RNA pellet was washed with 1 mL 
of 75% ethanol made with 0.01% DEPC water, mixed thoroughly by vortex and, 
centrifuged (Centrifuge 5415 R, Eppendorf) at 7,400 × g for 5 min at 4°C. The 
supernatant was discarded. The RNA pellet was air dried for 5-10 min at room 
temperature inside a fume cupboard and resuspended in 20 μL of 1X TE buffer (pH 
8.0). The purity of the RNA extracted was quantified with Nanodrop ND-1000 
spectrophotometer. The remaining RNA sample was stored at −80°C. 
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2.2.4.4 TRIzol RNA Extraction – Antimycin A Dose-Response Assays (2) 
3 mL of THP-1 cells (~5×10
5
 cells/mL) from the 6-well plate were centrifuged 
(Centrifuge 5415 R, Eppendorf) at 2000 × g for 7 min. The cell pellet was resuspend 
in 1 mL TRIzol. After resuspension, the TRIzol solution with pellet was transferred 
to sterile 1.5 mL Eppendorf tubes then incubated at 15-30°C for 5 min. 200 μL of 
chloroform was added, shaken vigorously by hand for 15 sec and incubated at 15-
30°C for 3 min. The mixture was centrifuged (Centrifuge 5415 R, Eppendorf) at 
12,000 × g for 15 min at 4°C. The upper colourless RNA layer was transferred to a 
new RNase-free tube. 500 μL of isopropanol was added to precipitate the RNA. The 
content was incubated at 15-30°C for 10 min and at −20°C for 20 min. This was then 
centrifuged (Centrifuge 5415 R, Eppendorf) at 12,000 × g for 10 min at 4°C. The 
supernatant was carefully removed. The RNA pellet was washed with 1 mL of 75% 
ethanol made with 0.01% DEPC water, mixed thoroughly by vortex and, centrifuged 
(Centrifuge 5415 R, Eppendorf) at 7,400 × g for 5 min at 4°C. The supernatant was 
discarded. The RNA pellet was air dried for 5-10 min at room temperature inside a 
fume cupboard and resuspended in 20 μL of 1X TE buffer (pH 8.0). The purity of the 
RNA extracted was quantified with Nanodrop ND-1000 spectrophotometer. The 
remaining RNA sample was stored at −80°C. 
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2.2.5 DNase Treatment of Total RNA 
The DNase treatment kit used was obtained from Invitrogen. The following 
components were prepared in an RNase-free tube. 
Table 7: Components used for DNase treatment 
RNA 1 μg 
10X Buffer 1 μL 
DNase I (1 U/μL) 1 μL 
0.01% DEPC H2O made up to 10 μL 
 
The tube was incubated at 37°C for 15 min. 1 μL of 25 mM EDTA was added as an 
exonuclease inhibitor. The solution was incubated at 65°C for 15 min to inactivate 
DNase I and returned to ice for 1 min. The product was collected by centrifugation at 
7,400 × g for 20 sec (Centrifuge 5415 R, Eppendorf) and stored at −80ºC. 
 
2.2.6 Formaldehyde Reducing Gel Electrophoresis 
2.2.6.1 Preparation of 10X MOPS Buffer (pH 7) 
3-(N-morpholino) propanesulfonic acid (MOPS) is a detergent that maintains the 
RNA integrity during electrophoresis. 400 mM of MOPS (AppliChem), 100 mM of 
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sodium acetate (Ajax Chemicals) and 10 mM of EDTA (BDH Laboratory Supplies) 
were dissolved in 0.01% DEPC water. The pH was adjusted to 7 then made up to 1 L 
with 0.01% DEPC water. 
 
2.2.6.2 Preparation of 1% Reducing Gel 
72 mL of 0.01% DEPC water was added to 1 g of agarose powder. The slurry was 
heated in a microwave to completely dissolve the agarose. 18 mL of 37% 
formaldehyde was added to the molten agarose solution and thoroughly mixed to 
make a 1% reducing gel. The gel was poured to be between 2-3 mm thick to give the 
best resolution. The addition of formaldehyde and the subsequent gel pouring were 
done in a fume hood. 
 
2.2.6.3 Sample Preparation 
The ingredients listed in Table 8 were added into an RNase-free tube for each sample. 
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Table 8: Components of each sample for formaldehyde reducing gel 
electrophoresis 
RNA 1 μg 
10X MOPS Buffer 2.5 μL 
37% Formaldehyde 3.5 μL 
Deionised Foramide (Sigma) 10 μL 
Ethidium Bromide (10 mg/mL Sigma) 1 μL 
Ficoll Gel Loading Dye 2 μL 
 
The mixture was heated at 65°C for 15 min, returned on ice for 2 minutes then 
collected by brief centrifugation (Centrifuge 5415 R, Eppendorf). 
 
2.2.6.4 Electrophoresis of RNA on Formaldehyde Reducing Gel 
The entire sample mixture was loaded and run with 1X MOPS buffer (pH 7.0) at 100 
V for 60 min. The gel was viewed under a UV illuminator/camera (Bio-Imaging 
Systems Ltd., DNR MiniBis Pro). 
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2.2.7 cDNA Synthesis with Reverse Transcriptase (RT) 
For each RNA sample, PCR-graded water (Invitrogen), 1 μg of RNA and 1 μL of 
Oligo(dT) were incubated at 65ºC for 10 minutes to linearise the secondary RNA 
structures before the actual cDNA synthesis (Invitrogen kit). After denaturation, 4 μL 
of 5X RT buffer, 0.5 μL of RNase Inhibitor, 0.5 μL of RT (Invitrogen) and 2 μL of 10 
mM dNTP were added to each RNA sample then incubated at 55ºC for 30 minutes. 
The RT activity was terminated by incubating at 85ºC for 5 minutes. A negative 
control with the RNA substituted by PCR-graded water was included. The cDNA was 
stored at −20ºC. 
 
2.2.8 Polymerase Chain Reaction (PCR) 
2.2.8.1 PCR – Trial 
Polymerase chain reactions were used to amplify DNA fragments of certain sizes 
(section 2.1.5). A house-keeping gene, human glyceraldehyde 3-phosphate 
dehydrogenase, GAPDH was used to compare the expression differences of human 
hsp60 and TNF-α. The PCR components and the 0.2 mL nuclease-free tubes were 
purchased from Invitrogen. The volumes and final concentrations of the components 
are listed in Table 9. The cDNA control was used in the PCR as negative controls. 
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Table 9: Volumes and concentrations of PCR components developed by co-
workers 
Component 1× (µL), GAPDH and Hsp60 Component 
1× (µL), TNF-
α 
cDNA 1 cDNA 0.5 
PCR buffer (1 
mM MgCl2 
finally) 
2.5 
PCR buffer (1 
mM MgCl2 
finally) 
2.5 
dNTP 0.5 dNTP 0.5 
forward primer 
(20 pmol) 
0.25 forward primer 0.5 
reverse primer (20 
pmol) 
0.25 reverse primer 0.5 
Taq Polymerase 
(5 U/µL) 
0.2 Taq Polymerase 0.2 
PCR water 19.3 PCR water 20.3 
Total 25 Total 25 
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Table 10: PCR conditions developed by co-workers 
Product 
Initial 
Denaturation 
Denaturation Annealing Extension 
Cycles of 
bold 
parts 
Final 
Extension 
GAPDH 
95°C, 4 min 95°C, 1 min 
60°C, 1 
min 
72°C, 1 
min 
24 
72°C, 10 
min 
Hsp 60 
55°C, 1 
min 
TNF-α 
60°C, 1 
min 
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2.2.8.2 PCR – After Antimycin A Dose-Response Assays 
As the TNF-α bands from normal THP-1 cells were very faint on 2% agarose gels, 
one PCR condition for the dose-response assays, TNF cDNA volume, was changed 
from 0.5 μL to 1 μL per sample, together with the decrease of respective water 
volume. This is to ensure the visibility of all PCR products on 2% agarose gels, if one 
gene of interest is down-regulated after the antimycin A treatment. 
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Table 11: Volumes and concentrations of PCR components developed by co-
workers 
Component 
1× (µL), GAPDH and 
Hsp60 
Component 
1× (µL), 
TNF-α 
cDNA 1 cDNA 1 
PCR buffer (1 
mM MgCl2 
finally) 
2.5 
PCR buffer (1 mM 
MgCl2 finally) 
2.5 
dNTP 0.5 dNTP 0.5 
forward primer 
(20 pmol) 
0.25 forward primer 0.5 
reverse primer 
(20 pmol) 
0.25 reverse primer 0.5 
Taq Polymerase 
(5 U/µL) 
0.2 Taq Polymerase 0.2 
PCR water 20.3 PCR water 19.8 
Total 25 Total 25 
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Table 12: PCR conditions used for antimycin A dose-response assays 
Product 
Initial 
Denaturation 
Denaturation Annealing Extension 
Cycles of 
bold parts 
Final 
Extension 
GAPDH 
95°C, 4 min 95°C, 1 min 
60°C, 1 
min 
72°C, 1 
min 
24 
72°C, 10 
min 
Hsp 60 
55°C, 1 
min 
TNF-α 
60°C, 1 
min 
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2.2.9 Non-reducing Agarose Gel Electrophoresis 
2.2.9.1 Preparation of 2% Agarose Gel 
Non-reducing agarose gel electrophoresis was used to separate DNA fragments of 
different sizes. 2 g of agarose powder was mixed with 100 mL of 1X SB buffer (pH 
8.5). The slurry was heated in a microwave oven till thoroughly melted. 2.5 μL of 10 
mg/mL ethidium bromide was added to the molten agarose. The agarose solution was 
cooled to approximately 60ºC then poured into either three mini-gel trays (Owl B1A) 
or a large one (Owl B2) and allowed to solidify. 
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2.2.9.2 Separation of PCR Products on Non-Reducing Agarose Gel 
The 3 μL of each PCR products plus 2 μL gel loading dye (Ficoll) were thoroughly 
mixed and loaded and run on a 2% agarose gel in 1X SB buffer (pH 8.5), at 80V for 
60 minutes. The agarose gel was viewed under a UV illuminator/camera (Bio-
Imaging Systems Ltd., DNR MiniBis Pro). A photo of the gel image was taken for 
band intensity analysis. In order to produce the highest possible resolution for 
intensity analysis, all electrophoresis photos were saved as .tif files. 
 
2.2.9.3 Quantitation of PCR Products with Gel Quant 
The area of the gel bands were calculated using Gel Quant software (DNR Imaging 
Systems Ltd., Gel Quant 2.7.0). To do so the Object Borders, Object Centres and 
Standards were firstly selected to be on. Both lanes and bands were analysed. The 
band areas were then adjusted to fit the actual bands. The calculated table of band 
areas was exported to a Microsoft Excel Workbook, after all the band areas were 
adjusted. The ratio of target gene expression/house keeping gene expression was 
further calculated. 
 
2.2.10 Statistical Analysis 
Tukey Multiple Comparisons of Means was applied to data from antimycin A dose-
response assays (2.2.2.1 and 2.2.2.2) using statistical programme R. 
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CHAPTER THREE 
ESTABLISHING A THP-1 
CELL LINE WITH 
COMPROMISED 
MITOCHONDRIAL 
FUNCTIONS 
3.1 Normal Growth of THP-1 Cells 
The THP-1 cell growth in normal RPMI 1640 medium is illustrated in Figure 1. After 
an initial lag phase from Day 0 to Day 1, there was a steady increase of 
approximately 2×10
4
 cells per day. 
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Figure 1: THP-1 cells grown in standard liquid medium (n = 3). 
Each error bar represents one standard deviation. 
 
3.2 THP-1 Cell Growth in Normal Medium plus Ethanol 
Since the mitochondrial inhibitor used in this assay, antimycin A, was dissolved in 
ethanol, the effect of this solvent on the growth of THP-1 monocytes was investigated. 
Figure 2 indicates that THP-1 cell growth was not affected by 5 μM of ethanol, but as 
the concentration increased from 10 μM to 200 μM, the growth rate gradually slowed 
down. For 5 μM of ethanol, the viable cell number was very similar to the untreated 
control across all five days (Figure 2). For 10, 25 and 50 μM of ethanol, there were 
approximately 10
4
 cells less than the untreated control on Day 4, approximately 5000 
cells less than the untreated control on Day 3, but no differences in viable cell 
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concentrations before Day 3 compared to the untreated control (Figure 2). For 100 
and 200 μM of ethanol, there were approximately 2×104 less cells than the untreated 
control on Day 4, and approximately 10
4 
less cells than the untreated control on Day 
3 (Figure 2). 
 
Figure 2:THP-1 cells maintained in RPMI medium containing 0 (U = untreated 
control), 5, 10, 25, 50, 100 or 200 μM of ethanol respectively (n = 3). 
Each error bar represents one standard deviation. 
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dependent on the concentration, compared to the untreated control. The conditioned 
growth medium of THP-1 monocytes treated with antimycin only was yellower than 
untreated and solvent controls. According to Figure 3, there was still some cell 
growth in 5 (approximately 2×10
4
 more on Day 4 than Day 0) and 10 μM 
(approximately 10
4
 more on Day 4 than Day 0) of antimycin A, although the rate was 
severely restricted. Cells in 25 and 50 μM of antimycin A remained viable but could 
not grow to increase the population; whereas ones in 100 and 200 μM of antimycin A 
only decreased because the levels of inhibitor were too toxic (Figure 3). 
 
Figure 3: THP-1 cells maintained in RPMI medium containing 0 (U, untreated 
control), 5, 10, 25, 50, 100 or 200 μM of antimycin A respectively (n = 3). 
Each error bar represents one standard deviation. 
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A comparison of untreated and solvent controls against respective antimycin A 
concentrations (Figure 4) shows that the severe inhibition of THP-1 cell-growth in the 
presence of antimycin A is not due to the solvent, even though the growth rate 
slightly decreased if ethanol is present, as discussed in 3.2. 
 
Figure 4: THP-1 cells grown in media containing various antimycin A 
concentrations compared with respective controls (n = 3). 
U = untreated control. Each error bar represents one standard deviation. 
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3.4 Redox Rescue 
In order to see if the growth inhibitory effect of antimycin A could be overcome or 
ameliated by redox rescue agents, THP-1 monocytes were grown in the presence of 
pyruvate and uridine. 50 μg/mL uridine and 1 mM sodium pyruvate were included in 
the media for pyrimidine biosynthesis (uridine) and redox sink molecule or redox 
rescuer (pyruvate) as discussed in 2.2.2.2, combining with 5, 10, 25, 50, 100 or 200 
μM of antimycin A respectively. The conditioned growth medium of THP-1 
monocytes treated with antimycin A, uridine and pyruvate was yellower than 
respective untreated and solvent controls. Yet it was as yellow as the cells having 
antimycin A only. Uridine and pyruvate allowed the viable cell numbers in 5, 10, 25 
and 50 μM of antimycin A to multiply faster than the cells without (Figure 5). 100 
and 200 μM of antimycin A were still too toxic to THP-1 cells so they rapidly 
deceased (Figure 5). 
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Figure 5: THP-1 cells maintained in RPMI medium containing 50 μg/mL 
uridine, 1 mM sodium pyruvate, together with 0 (U, untreated control), 5, 10, 25, 
50, 100 or 200 µM of antimycin A respectively (n = 3). 
Each error bar represents one standard deviation. 
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Figure 6: THP-1 cells grown in media containing various antimycin A 
concentrations including redox rescuers, compared with respective controls (n = 
3). 
U = untreated control. Each error bar represents one standard deviation. 
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including their solvent controls compared to respective untreated controls. However, 
the antimycin A treated samples were significantly different from their respective 
solvent and untreated controls. This is the same when uridine and pyruvate were 
added. Solvent controls were not significantly different compared to untreated 
controls in all parameters. 
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Table 13: p values obtained from each antimycin A concentrations using Tukey 
Multiple Comparisons of Means. 
Red figures indicated no statistical significance (p value > 0.05). 
 
p value of Tukey 
Multiple Comparisons 
of Means 
[Antimycin A] (μM) 
5 10 25 50 100 200 
AA only solvent vs AA 0.0000213 0.0000856 0.0002483 0.0000002 0.0000000  0.0000005 
AA only U vs AA 0.0000319 0.0000150  0.0000204 0.0000000  0.0000000  0.0000000  
AA vs AA + UP 0.2466417 0.2583839 0.4948712 0.4348168 0.9973485 1.0000000  
AA only U vs AA only 
solvent 
0.9993070  0.7290985 0.4385034 0.1779117 0.7829941 0.0786210  
UP solvent vs AA + UP 0.0000077 0.0000074 0.0000119 0.0000000  0.0000000  0.0000000  
UP U vs AA + UP 0.0000014 0.0000012 0.0000021 0.0000000  0.0000000  0.0000000  
UP U vs UP solvent 0.5910283 0.5219193 0.6242867 0.1779117 0.1233147 0.1406779  
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Table 14: Legend for Table 13 
Legend Description 
AA Antimycin A without uridine, pyruvate 
AA only solvent Solvent control without uridine, pyruvate 
AA only U Untreated control without uridine, pyruvate 
AA + UP Antimycin A plus uridine, pyruvate 
UP solvent Solvent control plus uridine, pyruvate 
UP U Untreated control plua uridine, pyruvate 
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Figure 7: Antimycin A inhibition of THP-1 cell-growth plotted on the scale as 
Figure 8. 
Each error bar represents one standard deviation (n = 3). Figures 7 and 8 are to 
compare the THP-1 cell growth with or without uridinen pyruvate. 
 
Figure 8: Antimycin A inhibition of THP-1 cell-growth with the help of redox 
rescuers. Each error bar represents one standard deviation (n = 3). 
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CHAPTER FOUR TOTAL RNA 
EXTRACTION 
4.1 Trials of TRIzol RNA Extractions 
The detailed protocols of extracting total RNA from THP-1 monocytes were 
described in 2.2.4. A good RNA extraction is defined by three criteria: RNA quantity, 
purity and integrity. These determine if the extracted RNA is at the optimal condition 
and applicable for follow-on experimental work. The quantity of RNA needed varies 
from assays to assays. For example, the detection of RNA integrity using 
formaldehyde reducing gel requires at least 500 ng of total RNA; however only 10 ng 
to 5 μg of RNA is enough for cDNA synthesis (Roche). RNA purity is commonly 
measured by the spectrophotometric absorbance ratio of 260/280 nm (A260/280). RNA 
samples free from protein and DNA contaminations generally give A260/280 from 1.9 
to 2.1. 
 
Yet an acceptable A260/280 ratio gives no indications that the RNA extracted is still 
intact. A highly pure RNA sample can be totally degraded into pieces that although 
enough added to cDNA synthesis and PCR, no useful results can be obtained. The 
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integrity of mammalian RNA is defined by two distinct bands of 18S and 22S 
ribosomal RNA (rRNA) when separated by formaldehyde reducing gel 
electrophoresis. These rRNA compose of approximately 50% of the total RNA in 
mammalian cells. If the RNA is degraded, a smear instead of distinct bands, along the 
track would be expected on a formaldehyde gel after electrophoresis. 
 
4.1.1 TRIzol RNA Extraction – Attempt One 
THP-1 monocyte cells grown in normal growth medium were used to ensure the 
extraction protocol was applicable for this project. Four random samples (THP-1 
R1−R4) from the same culture flask were used. The volumes of these samples were 
all 1 mL with concentrations approximately 10
5
 cells/mL. The method used was 
illustrated in 2.2.4.1. The A260/280 ratios of these RNA samples were 1.21−1.78, rather 
than 1.9−2.1. This shows that the RNA was impure. 
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Table 15: The first attempt of TRIzol RNA extraction 
Sample ID ng/µL 260/280 
THP-1 R1 277.92 1.21 
THP-1 R2 181.07 1.21 
THP-1 R3 1027.1 1.78 
THP-1 R4 153.88 1.51 
 
4.1.2 TRIzol RNA Extraction – Attempt Two 
After comparing with another protocol of RNA extraction from mammalian cells 
(Sambrook et al. 1989), it suggested that centrifuging at 13,000 rpm would lyse cells, 
thus losing RNA into supernatant. RNase stored in cells could be released therefore 
degrading some RNA. Moreover, precipitating RNA at room temperature may not be 
enough. This means further precipitation at −20ºC for 20 minutes could be needed. 
After several practices (data not shown) of the protocol in 2.2.4.3 the A260/280 ratios 
were finally within 1.9 and 2.1 (THP-1 R5.1−5.4) with good yield (565.80−1670.7 
ng/μL) were obtained. 
 
1 μg of linear RNA from each sample was visualised under a UV illuminator/camera 
(DNR Imaging Systems, Minibis Pro). According to the reducing gel electrophoresis, 
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RNA samples were all intact and the amount was improved from Attempt One 
(Figure 9, -10 and Table 16). Although some smears still existed, 18S and 22S rRNA 
bands from samples THP-1 R5.1−5.4 carried according to the protocol described, 
were clearly distinct (Figure 9). Since the extracted RNA was intact, DNase treatment 
was followed. 
 
Table 16: The acceptable yield of total RNA extraction with TRIzol 
Sample ID ng/µL 260/280 
THP-1 R5.1 565.80 1.98 
THP-1 R5.2 534.91 1.98 
THP-1 R5.3 1075.1 2.00 
THP-1 R5.4 1670.7 1.98 
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Figure 9: Total RNA extracted from THP-1 cells using TRIzol was run on a 1% 
formaldehyde reducing gel, before DNase treatment. 
The top band represented 18S rRNA, while the bottom indicated 22S rRNA. Lane 1 = 
blank, as the standard RNA was eliminated due to its old age; Lane 2−5 = RNA 
samples THP-1 R5.1−5.4. The RNA was intact, despite of some remaining 
contaminations as shown by the smears. 
 
RNA samples, THP-1 R5.1−5.4, were treated with DNase I (Invitrogen) using the 
protocol listed in 2.2.5. After DNase treatment, 1 μg of each RNA sample was run on 
1% formaldehyde reducing gel and viewed under a UV illuminator (DNR Imaging 
Systems Ltd., MiniBis Pro). The RNA samples were all intact, especially the 
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impurities were removed during DNase treatment, as indicated by less smears on each 
lane (Figure 10). 
 
Figure 10: After DNase treatment, 1 μg of RNA extracted from THP-1 cells 
using TRIzol was run on a 1% formaldehyde reducing gel. 
Lane 1 = blank; Lane 2−5 = RNA samples from THP-1 R5.1−5.4, the four random 
samples taken from cells grown in the same flask with standard growth medium. 
Contaminating DNA was taken away as the smears on the running tracks shown in 
Figure 9 disappeared. 
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4.2 RNA Extraction after Antimycin A Dose-Response Assays 
4.2.1 Attempt One 
The method of challenging THP-1 monocytes with various antimycin A 
concentrations was mentioned in 2.2.3. Total RNA extraction (protocol 2.2.4.3) using 
TRIzol (Invitrogen) was done after antimycin A challenge. Approximately 5×10
4
 
cells/mL was used in each triplicate to extract total RNA. The extraction conditions 
and reagents used were identical as 2.2.4.2, except that 1 mL of suspended THP-1 
cells from each triplicate was taken from each triplicate, and the RNA solution of 
triplicates with the same antimycin A concentrations were combined into one RNase-
free tube. 
 
The RNA yields obtained after antimycin A treatment was not good with the first 
attempt, with A260/280 ratios ranging from 1.37 to 1.86, and yield between 33.36 and 
482.02 ng/μL. This could be due to the low viable cell concentration remained after 
five days of mitochondrial inhibitor challenge, since the A260/280 ratios of solvent and 
untreated controls without uridine and pyruvate were still acceptable (Table 17). 
Using higher cell concentration at the initial stage of challenge was then attempted 
(protocol 2.2.3.2). 
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Table 17: RNA yield after TRIzol RNA extraction (1) 
Sample ID ng/µL 260/280 Sample ID ng/µL 260/280 
5 µM 146.99 1.79 UP 5 µM 81.4 1.46 
10 µM 138.64 1.69 UP 10 µM 102.34 1.49 
25 µM 304.75 1.70 UP 25 µM 134.48 1.66 
50 µM 120.63 1.61 UP 50 µM 36.67 1.37 
100 µM 106.26 1.41 UP 100 µM 71.08 1.41 
200 µM 33.36 1.83 UP 200 µM 83.76 1.57 
0/5 µM 337.72 1.98 UP 0/5 µM 276.01 1.72 
0/10 µM 349.69 1.95 UP 0/10 µM 408.38 1.79 
0/25 µM 384.53 1.86 UP 0/25 µM 458.53 1.86 
0/50 µM 363.74 1.95 UP 0/50 µM 150.54 1.51 
0/100 µM 393.60 1.91 UP 0/100 µM 482.02 1.72 
0/200 µM 375.27 1.98 UP 0/200 µM 303.18 1.49 
U 371.80 1.91 UP U 517.61 1.79 
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4.2.2 Attempt Two 
The antimycin A challenge was repeated with THP-1 monocytes again, as explained 
in 2.2.3.2. For each replicate, the initial cell concentration was raised from 1.84×10
4
 
to 1×10
5
 cells/mL. All cells were used to extract total RNA instead of just 1 mL. The 
purity and yield of the second attempt were much better than the first one (Table 18). 
All A260/280 ratios reached above 1.9, plus the yield ranged from 566.00 to 3430.0 
ng/μL; apart from cells grown in 25 and 50 μM of antimycin A. The low purity and 
yield of these two replicates could be due to the few viable cells surviving after five 
days of antimycin A treatment (Table 18). 
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Table 18: RNA yield after TRIzol RNA extraction (2) 
Sample ID ng/µL A260/280 Sample ID ng/µL A260/280 
5 µM 1150.2 2.03 UP 5 µM 1399.8 2.03 
10 µM 1593.0 2.02 UP 10 µM 1573.2 2.03 
25 µM 20.69 1.53 UP 25 µM 828.67 2.03 
50 µM 6.53 1.36 UP 50 µM 566.00 1.94 
U 3430.0 1.94 UP U 3255.5 1.95 
 
The RNA was further purified with DNase using the protocol listed in 2.2.5. 1 μg of 
these DNase-treated RNA was then run on 1% formaldehyde reducing gel (protocol 
2.2.6). The results after reducing gel electrophoresis are in Figure 11 and Figure 12. 
All RNA was intact and present in good quantity for samples UP 5−50 μM, which 
were extracted from THP-1 cells exposed to 5−50 μM antimycin A plus uridine and 
pyruvate. Yet the RNA from 10 μM antimycin A treatment was degraded 
immediately after extraction; plus the yield from 25 and 50 μM were very low 
(Figure 11). Also some RNA from the untreated sample (U) degraded, as shown at 
the bottom of the formaldehyde gel (Figure 11). Despite so, these DNase-treated 
RNA was still used for cDNA synthesis and PCR, as most of the extractions worked 
well. 
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Figure 11: Reducing gel showing total RNA extracted from THP-1 cells after 
five days of antimycin A treatment, after DNase treatment. 
Lane 1 = 18S + 22S standard rRNA (Sigma); Lane 2−Lane 5 = 5, 10, 25, 50 μM 
antimycin A and Lane 6 = untreated control (U). RNA from THP-1 cells grown in 10 
μM antimycin A was degraded instantly after extraction. This is why no bands could 
be seen in Lane 3 but with a smear at the lower part of the gel instead. RNA from 
THP-1 cells grown in 25 μM antimycin A had lower yield, so the bands were very 
faint on a reducing gel. RNA amount from THP-1 cells grown in 25 μM antimycin A 
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was even worse; therefore no bands could be detected. Some contaminations, 
possibly from DNA, are still present at the top of each well. 
 
 
Figure 12: Reducing gel showing total RNA extracted from THP-1 cells after 
five days of antimycin A plus uridine and pyruvate treatment (denoted as UP), 
after DNase treatment. 
Lane 1 = 18S + 22S standard rRNA (Sigma); Lane 2 = UP 5; Lane 3 = UP 10; Lane 4 
= UP 25; Lane 5 = UP 50 μM antimycin A and Lane 6 = UP untreated control (UP U). 
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CHAPTER FIVE REVERSE 
TRANSCRIPTASE-
POLYMERASE CHAIN 
REACTION (RT-PCR) 
The polymerase chain reaction (PCR) was invented by Kary Mullis in 1980 
(Wikowski & Zoller, 2001) as a technique of replicating certain regions of DNA. It is 
sensitive enough to amplify from very small amount of DNA templates. PCR has 
extremely wide applications in laboratories because of its efficient and straight 
forward operation. 
 
In a generic PCR process, a piece of double-stranded DNA is first denatured at 94ºC 
for five minutes to become linear, single-stranded DNA. Oligonucleotide primers are 
used as starting points of replications. These primers have specific sequences so they 
can anneal to the beginning and the end of a DNA fragment or region. The annealing 
temperature varies from gene to gene, but is generally between 50 and 60ºC. After 
annealing, an extension step is used by adding single nucleotides (dNTP) between the 
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forward (from the beginning) and the reverse (from the end) primers with the help of 
a heat resistant enzyme, Taq polymerase. The temperature for extension is 
approximately 72ºC. With 25−40 replicating cycles one can generate enough DNA 
copies that are detectable via non-reducing agarose gel electrophoresis. 
 
The precise PCR conditions depend on different genes and sample types. Commonly 
adjusted conditions are: the amount of DNA template, Mg
2+
 concentration, annealing 
temperatures and number of cycles. Mg
2+
 concentration is crucial because the ion 
interacts with primers, affecting the annealing results of primers. The cycle number 
needs to be changed as not all templates exist in equal number of copies. In other 
words not all genes are expressed in the same intensity. For the ones that express 
more, more copies of associated mRNA is present in the total RNA. These genes are 
referred as “high copy number” genes. In contrast, for the “low copy number” genes, 
more replicating cycles are needed in order to visualise on agarose gel electrophoresis. 
However, one needs to make sure that the cycle number is not too many; otherwise 
the products will over-saturate the solution, causing it to be very viscous. This means 
that molecules are hard to move around in solution, so some of the procedures such as 
extension may be incomplete. In such circumstance, the gene expression level may 
not be accurately represented due to incomplete extension steps. 
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In this project, a constitutively expressed gene, or house keeping gene is used to show 
that the expression differences between genes are indeed due to different dose-
response treatments, instead of operational or systematic errors. The expression can 
be stated as a ratio of target gene expression/house keeping gene expression. 
 
5.1 RT-PCR Trial 
RNA samples, 5.1−5.4 as mentioned in Table 16, were used to run RT-PCR trials to 
ensure that all reagents functioned appropriately (protocols 2.2.7 and 2.2.8.1). A 
house keeping gene, human glyceraldehydes 3-phosphate dehydrogenase (GAPDH), 
was used as a control to normalise the gene expression of human Hsp60 and TNF-α. 
The primer sequences of these three genes were listed in 2.1.8. 
 
The PCR results were produced according to the optimised conditions developed by 
other co-workers. The band intensities for GAPDH and Hsp60 were within the visible 
range, yet the TNF-α bands were too faint (Figures 13 and 14). If the TNF-α 
expression is down-regulated in the antimycin A dose-response assay, the bands may 
be invisible. Thus the TNF-α cDNA volume was increased to 1 μL for the dose-
response assays. 
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Figure 13: RT-PCR of GAPDH, Hsp60 and TNF-α. 
Lane 1−3, GAPDH, Hsp60 and TNF-α (R5.1); Lane 4−6, GAPDH, Hsp60 and TNF-
α (R5.2); Lane 7−9, GAPDH, Hsp60 and TNF-α (R5.3); Lane 10, 100 bp ladder. 
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Figure 14: RT-PCR of GAPDH, Hsp60 and TNF-α with respective negative 
controls. 
Lane 1−3, GAPDH, Hsp60 and TNF-α (R5.4); Lane 4−6, negative controls of 
GAPDH, Hsp60 and TNF-α PCR; Lane 7, 100 bp ladder. 
 
5.2 RT-PCR After Antimycin A Dose-Response Assay 
The RT-PCR results after antimycin A dose-response assay (2.2.3.2) and total RNA 
extraction (2.2.4.4) is shown in Figure 15. The detailed method is stated in 2.2.7 and 
2.2.8.2. No detectable contaminations were observed according to the negative 
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controls of human GAPDH, Hsp60 and TNF-α PCR. Most of the PCR products were 
visible on the 2% non-reducing agarose gel, apart from samples 10 and 50 μM 
antimycin A only. No detectable products could be found for THP-1 monocytes 
grown in these two conditions. There were two reasons for such failed PCR. The 
RNA was found to be degraded after extraction (Figure 11) in sample 10 μM 
antimycin A only; and the purity as well as yield were too low for 50 μM antimycin 
A only (Table 18). According to Figure 15, GAPDH, Hsp60 and TNF-α expression 
was all down-regulated in response to increasing antimycin A concentration, when no 
uridine and pyruvate were added. When uridine and pyruvate were applied, GAPDH 
showed almost no change in expression in response to increasing antimycin A 
concentration; a slight up-regulation was observed in both Hsp60 and TNF-α. 
Notably, TNF-α expression was extremely low in antimycin A only conditions. 
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Figure 15: The RT-PCR products were run on a 2% non-reducing agarose gel. 
Label starts from the top left: Lane 1, 100 bp ladder, Lane 2−5: GAPDH expression 
of 5, 10, 25, 50 μM antimycin A only; Lane 6, untreated control of antimycin A only; 
Lane 7−10 GAPDH expression of 5, 10, 25, 50 μM antimycin A plus uridine, 
pyruvate, Lane 11, untreated control of antimycin A plus uridine, pyruvate; Lane 12, 
negative control of GAPDH PCR; Lane 13−16, Hsp60 expression of 5, 10, 25, 50 μM 
antimycin A only, Lane 17, untreated control of antimycin A only; Lane 18−22 
(excluding 100 bp ladder), Hsp60 expression of 5, 10, 25, 50 μM antimycin A plus 
uridine, pyruvate; Lane 23, untreated control of antimycin A plus uridine, pyruvate; 
Lane 24, negative control of Hsp60 PCR; Lane 25−28, TNF-α expression of 5, 10, 25, 
50 μM antimycin A only; Lane 29, untreated control of antimycin A only; Lane 
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30−34, TNF-α expression of 5, 10, 25, 50 μM antimycin A plus uridine, pyruvate; 
Lane 35, untreated control of antimycin A plus uridine, pyruvate; Lane 36, negative 
control of TNF-α PCR. Lane 31 is a repeated loading from the same PCR product of 
TNF-α expression in 10 μM antimycin A plus uridine and pyruvate. 
 
5.3 Quantification of Band Areas 
The following description relates to Figures 16, -17 and Table 19. Ratios closer to 
one when compared against GAPDH indicate higher expression. UP-treated THP-1 
monocytes had higher expression level of both Hsp60 and TNF-α in all antimycin A 
concentrations, including untreated controls, relative to the respective antimycin A 
only conditions. The expression of Hsp60 was more elevated than TNF-α in all 
antimycin A concentrations, including UP-treated and untreated controls. Hsp60 
expression was down-regulated in response to increasing antimycin A concentration, 
compared to the untreated control. Yet this was reversed when uridine and pyruvate 
were added. 25 μM antimycin A with uridine and pyruvate (UP Hsp60 25), possibly 
an outlier, showed even higher expression of hsp60 compared to the corresponding 
control (UP Hsp60 U). On the other hand, both antimycin A only and AA + UP 
resulted in up-regulated TNF-α expression. Surprisingly, TNF-α expressions in 
antimycin A only conditions were very low, that the bands for 5 (TNF-α 5) and 25 
μM (TNF-α 25) were hardly visible. This did not happen when uridine and pyruvate 
were added. The particular up-regulated TNF-α expression in 50μM antimycin A plus 
UP could also be an outlier. For all three genes of interest, PCR products from 10 and 
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50 μM of antimycin A only did not show up as the RNA was immediately degraded 
after extraction in 10 μM, which was seen as a smear at the lower part of the 
formaldehyde gel (Figure 11), and the RNA yield for 50 μM was too low (Table 18). 
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Table 19: Band areas of PCR products were quantified and normalised against 
GAPDH expressions using Gel Quant software (table continued through page 73 
to 75). 
GAPDH or GAP = human GAPDH gene; Hsp60 = human Hsp60 gene; TNF-α = 
human TNF-α gene. U = untreated control; UP = uridine and pyruvate were added; 5, 
10, 25, 50 = respective antimycin A concentrations in μM. Band areas for 10 and 50 
μM antimycin A only were missing because a) RNA from 10 μM antimycin A 
treatment was degraded immediately after extraction and b) the RNA yield from 50 
μM antimycin A treatment was too low to produce PCR products. 
Gene, AA Conc Area gene/GAPDH 
GAPDH 5 159718 1 
GAPDH 10 0 0 
GAPDH 25 96046 1 
GAPDH 50 0 0 
GAPDH U 147815 1 
UP GAP 5 164737 1 
UP GAP 10 149606 1 
UP GAP 25 140249 1 
UP GAP 50  154547 1 
UP GAP U 151802 1 
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Gene, AA Conc Area gene/GAPDH 
Hsp60 5 101957 0.6384 
Hsp60 10 0 0 
Hsp60 25 41362 0.4306 
Hsp60 50 0 0 
Hsp60 U 107043 0.7242 
UP Hsp60 5 113140 0.6868 
UP Hsp60 10 118726 0.7936 
UP Hsp60 25 138456 0.9872 
UP Hsp60 50 133055 0.8609 
UP Hsp60 U 139472 0.9188 
TNF-α 5 4522 0.0283 
TNF-α 10 0 0 
TNF-α 25 7834 0.0816 
TNF-α 50 0 0 
TNF-α U 70972 0.4801 
UP TNF-α 5 77390 0.4698 
75 
 
Gene, AA Conc Area gene/GAPDH 
UP TNF-α 10 41414 0.2768 
UP TNF-α 25 77433 0.5521 
UP TNF-α 50 111719 0.7229 
UP TNF-α U 77232 0.5088 
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Figure 16: Gene expression of human Hsp60 normalised with human GAPDH in 
THP-1 monocytes, after various concentrations of antimycin A challenge (5, 10, 
25 and 50 μM), with or without 50 μg/mL uridine and 1 mM sodium pyruvate (n 
= 1). 
U = untreated control; UP = uridine and pyruvate were added. 
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Figure 17: Gene expression of human TNF-α normalised with human GAPDH 
in THP-1 monocytes, after various concentrations of antimycin A challenge (5, 
10, 25 and 50 μM), with or without 50 μg/mL uridine and 1 mM sodium 
pyruvate (n = 1). 
U = untreated control; UP = uridine and pyruvate were added. 
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CHAPTER SIX DISCUSSION 
6.1 Antimycin A Dose-Response Assays with THP-1 Monocytes 
The antimycin A inhibition on THP-1 cells was dose-dependent. The conditioned 
media after antimycin A treatment was yellower than the controls. Since cells with 
compromised mitochondrial activities convert pyruvate to lactate in order to generate 
NAD
+
, and the yellow media indicates increased acidity, we interpreted that there 
were some mitochondrial stress or damage in THP-1 monocytes. Ethanol, as the 
solvent for antimycin A, did not significantly change the growth rate of THP-1 
monocytes relative to the untreated controls, either (Table 13). Interestingly, the 
application of uridine and pyruvate did not significantly increase THP-1 cell growth 
under the exposure of antimycin A. This could be due to the high concentration of 
antimycin A used that over-rode the redox rescue effect, as only 5−25 nM antimycin 
A were added to HL60 cells (Mills et al., 1999). It is therefore worth treating THP-1 
monocytes with lower antimycin A concentrations in the future to test the functioning 
of redox rescuing compounds. 
 
From this series of experiments we know how many live cells there were on each day. 
However we did not measure the activity of mitochondrial complexes, so we do not 
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know exactly how much mitochondrial stress/inhibition there was with various 
antimycin A concentrations. Besides, MAPK/ERKs activated by hydrogen peroxide-
mediated oxidative stress model was found to be ATP- and mitochondrion-dependent 
in H9c2 cells (Abas et al., 2000). Because Hsp60 was found to activate NF-κB 
through similar signal cascade, the activities of such signal pathway could also be 
assessed while antimycin A or other mitochondrial inhibitors are used in the future. 
 
Triplicates are only the minimal sample size for statistical analysis. The replications 
for each antimycin A concentration of dose-response assays could be increased to 
obtain better statistical analyses. The exposure time of antimycin A to THP-1 
monocytes could be increased to monitor the long-term effect of mitochondrial stress. 
 
6.2 TRIzol RNA Extraction 
Total RNA from THP-1 monocytes after five days of exposure to various antimycin 
A concentrations were extracted using TRIzol and chloroform. Solvent controls were 
eliminated as they were shown not to significantly change THP-1 cell growth 
compared to the untreated controls (Table 13). The mRNA of human GAPDH, Hsp60 
and TNF-α expressed by THP-1 monocytes after the five-day dose-response assay 
were determined by RT-PCR. 
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TRIzol (Invitrogen) -chloroform successfully extracted total RNA out of THP-1 
monocytes when the cell concentration was at least 10
5
 cells/mL. The centrifuging 
speed for making cell pellet was crucial for good purity and amount of RNA 
extracted. If too low, not enough cells could be retained to extract RNA. If the speed 
was too high, the cells would be lysed thus losing RNA into supernatant, as well as 
degradation occurring via released RNases. The crude RNA still contained some 
DNA residues because the product was not filtered through a column like some RNA 
extraction kits do. The purity and amount were therefore more dependent on an 
operator’s skill. The reason for a complete degradation of RNA straight after 
extraction (Figure 11) remains to be discovered. 
 
6.3 RT-PCR 
It is well-known that stress proteins such as Hsp60 can be up-regulated during 
cellular and/or mitochondrial stress (Martinus et al., 1996), and Hsp60 can be cyto-
protective and anti-apoptotic (Kirchhoff et al., 2002). We checked to see if THP-1 
cells treated with antimycin A had higher levels of Hsp60 expression at the mRNA 
level. Since THP-1 is also a monocytic cell line, we decided to also see if inhibiting 
mitochondrial function via antimycin A has any effects on the ability of cells to 
modulate TNF-α expression. 
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The RT-PCR functioned correctly. No detectable contaminations showed up 
according to the negative controls (Figure 14 and -15). Total RNA extracted from 
THP-1 monocytes, after antimycin A dose-response assays were used to run RT-PCR. 
We know the extent of human GAPDH, Hsp60 and TNF-α mRNA level after five 
days of antimycin A exposure by viewing the results from non-reducing agarose gel 
electrophoresis. The band areas on the agarose gel were quantified using Gel Quant 
software. The amount of Hsp60 and TNF-α mRNA was compared against GAPDH 
and expressed as ratios of Hsp60 band area/corresponding GAPDH band area or 
TNF-α band area/corresponding GAPDH band area (Table 19). 
 
Yet we do not know the amount of GAPDH, Hsp60 and TNF-α mRNA produced 
during the previous four days of antimycin A dose-response assay. Quantitative real-
time PCR could be done in the future to closely monitor the gene expression of THP-
1 monocytes undergoing mitochondrial stress/dysfunction. 
 
The Hsp60 gene expression level, as seen by mRNA in Figure 16, decreased with 
increasing antimycin A concentration when no uridine and pyruvate (UP) were added 
to THP-1 monocytes, but Hsp60 was up-regulated as antimycin A concentration 
raised in the presence of UP. It could be that the up-regulated Hsp60 in UP-treated 
THP-1 monocytes was to respond to the enhanced mitochondrial stress as the 
antimycin A concentration increased. However this does not explain why down-
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regulation of Hsp60 was seen in THP-1 monocytes treated with antimycin A only. Or 
else the increased Hsp60 mRNA in UP-treated monocytes could simply be due to 
higher cell density, since some up-regulation of Hsp60 was seen in the UP untreated 
control. Moreover, Hsp60 is also seen as a danger signal in the immune system and 
has inflammatory induction effects. It has been shown that adding recombinant 
human Hsp60 to THP-1-derived macrophages can induce them to produce TNF-α at a 
level comparable to bacterial Hsp60 (Ueki et al., 2002); and monocytes are known to 
detect one’s own Hsp60 through cell surface receptors such as TLR4 to activate NF-
κB then produce TNF-α (Yang et al., 2008). The role(s) of Hsp60 in monocytes with 
compromised mitochondrial functions thus need to be further investigated. 
 
The TNF-α expression in THP-1 monocytes exposed to only antimycin A was down-
regulated relative to the untreated control that the bands were hardly visible on the 
agarose gel (Figure 17). This kind of dramatic down-regulation of TNF-α was not 
detected in the corresponding antimycin A concentrations together with uridine and 
pyruvate. Uridine and/or pyruvate may have other functions in cells apart from redox 
rescue and pyrimidine biosynthesis fulfilment. The reason for such expression 
difference also remains to be determined as no literatures at this stage could be found 
to explain so. 
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Although both Hsp60 and TNF-α expressions were up-regulated in THP-1 monocytes 
treated with antimycin A, uridine and pyruvate (UP), there appears to be minor 
differences in the expression of these two genes. The expression of Hsp60 mostly did 
not exceed the UP untreated control, even though elevated (Figure 16). Nevertheless, 
TNF-α expressions were mainly more strongly or equal to the UP untreated control 
(Figure 17). Investigating the reason underlying could also be another future direction. 
 
The major short fall of this series of RT-PCR work is that no repetitions were done (n 
= 1). This means no statistical analyses could be carried out to normalise operational 
and systematic errors. Such errors can be amplified if the expression levels are very 
low, as in the case of TNF-α. Moreover, errors can occur while manually selecting 
band areas to analyse with Gel Quant. More replications of the whole set of 
experiment, from does-response assay to RT-PCR, along with appropriate statistical 
analyses should be done before drawing any conclusions. Additionally, GAPDH, 
Hsp60 and TNF-α expression may be checked at the protein level via Western Blot 
and enzyme-linked immunosorbent assay (ELISA) to confirm their up- or down-
regulations. These could also be the future work of this project. 
84 
 
REFERENCES 
Abas, L., Bogoyevitch, M. A. & Guppy, M. 2000. Mitochondrial ATP production is 
necessary for activation of the extracellular-signal-regulated kinases during 
ischaemia/reperfusion in rat myocyte-derived H9c2 cells. Biochemical Journal, 349, 
119-126. 
Alcain, F. J., Buron, M. I., Villalba, J. M. & Navas, P. 1991. Ascorbate is 
regenerated by HL-60 cells through the transplasmalemma redox system. Biochimica 
et Biophysica Acta, 1073, 380-385. 
Arsenijevic, D., Onuma, H., Pecqueur, C., Raimbault, S., Manning, B. S., 
Miroux, B., Couplan, E., Alves-Guerra, M. C., Goubern, M., Surwit, R., 
Bouillaud, F., Richard, D., Collins, S. & Ricquier, D. 2000. Disruption of the 
uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen 
species production. Nature Genetics, 26, 435-439. 
Auwerx, J. 1991. The human leukemia cell line, THP-1: a multifacetted model for 
the study of monocyte-macrophage differentiation. Experientia, 47, 22-31. 
Bailey, S. M., Landar, A. & Darley-Usmar, V. 2005. Mitochondrial proteomics in 
free radical research. Free Radical Biology and Medicine, 38, 175-188. 
Bozner, P., Wilson, G. L., Druzhyna, N. M., Bryant-Thomas, T. K., LeDoux, S. 
P., Wilson, G. L. & Pappolla, M. A. 2002. Deficiency of chaperonin 60 in Down's 
syndrome. Journal of Alzheimer's Disease, 4, 479 - 486  
85 
 
Centonze, D., Finazzi-Agro, A., Bernardi, G. & Maccarrone, M. 2007. The 
endocannabinoid system in targeting inflammatory neurodegenerative diseases. 
Trends in Pharmacological Sciences, 28, 180-187. 
Chen, W., Syldath, U., Bellmann, K., Burkart, V. & Kolb, H. 1999. Human 60-
kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System. J Immunol, 
162, 3212-3219. 
del Castillo-Olivares, A., de Castro, I. N. & Medina, M. A. 2000. Dual role of 
plasma membrane electron transport systems in defense. Critical Reviews in 
Biochemistry and Molecular Biology, 35, 197-220. 
Droge, W. 2002. Free Radicals in the Physiological Control of Cell Function. Physiol. 
Rev., 82, 47-95. 
Elias, D., Reshef, T., Birk, O. S., van der Zee, R., Walker, M. D. & Cohen, I. R. 
1991. Vaccination Against Autoimmune Mouse Diabetes with a T-Cell Epitope of the 
Human 65-kDa Heat Shock Protein. Proceedings of the National Academy of 
Sciences, 88, 3088-3091. 
Esiri, M. M. 2007. The interplay between inflammation and neurodegeneration in 
CNS disease. Journal of Neuroimmunology, 184, 4-16. 
Firth, A. L., Yuill, K. H. & Smirnov, S. V. 2008. Mitochondria-dependent 
regulation of Kv currents in rat pulmonary artery smooth muscle cells. American 
Journal of Physiology-Lung Cellular and Molecular Physiology, 295, L61-L70. 
86 
 
Fleury, C., Mignotte, B. & Vayssiere, J. L. 2002. Mitochondrial reactive oxygen 
species in cell death signaling. Biochimie, 84, 131-141. 
Garret, R. H. & Grisham, C. M. 2005. Biochemistry. In: Biochemistry. Belmont: 
Thomson Brooks/Cole. 
Giardina, T. M., Steer, J. H., Lo, S. Z. Y. & Joyce, D. A. 2008. Uncoupling 
protein-2 accumulates rapidly in the inner mitochondrial membrane during 
mitochondrial reactive oxygen stress in macrophages. Biochimica Et Biophysica 
Acta-Bioenergetics, 1777, 118-129. 
Gómez-Díaz, C., Villalba, J. M., Pérez-Vicente, R., Crane, F. L. & Navas, P. 
1997. Ascorbate Stabilization Is Stimulated in [rho]°HL-60 Cells by CoQ10Increase 
at the Plasma Membrane. Biochemical and Biophysical Research Communications, 
234, 79-81. 
Guidarelli, A., Sciorati, C., Clementi, E. & Cantoni, O. 2006. Peroxynitrite 
mobilizes calcium ions from ryanodine-sensitive stores, a process associated with the 
mitochondrial accumulation of the cation and the enforced formation of species 
mediating cleavage of genomic DNA. Free Radical Biology and Medicine, 41, 154-
164. 
Gupta, R. S. & Austin, R. C. 1987. Mitochondrial Matrix Localization of a Protein 
Altered in Mutants Resistant to the Microtubule Inhibitor Podophyllotoxin. Eur J Cell 
Bio, 45, 170-176. 
87 
 
Gupta, S. & Knowlton, A. A. 2007. HSP60 trafficking in adult cardiac myocytes: 
role of the exosomal pathway. American Journal of Physiology-Heart and 
Circulatory Physiology, 292, H3052-H3056. 
Halliwell, B. 1992. Reactive oxygen species and the central-nervous-system. Journal 
of Neurochemistry, 59, 1609-1623. 
Halliwell, B. 2001. Role of free radicals in the neurodegenerative diseases - 
Therapeutic implications for antioxidant treatment. Drugs & Aging, 18, 685-716. 
Hartl, F. U. 1996. Molecular chaperones in cellular protein folding. Nature, 381, 
571-580. 
Huang, L.-s., Cobessi, D., Tung, E. Y. & Berry, E. A. 2005. Binding of the 
Respiratory Chain Inhibitor Antimycin to the Mitochondrial bc1 Complex: A New 
Crystal Structure Reveals an Altered Intramolecular Hydrogen-bonding Pattern. 
Journal of Molecular Biology, 351, 573-597. 
Hyun, D. H., Hunt, N. D., Emerson, S. S., Hernandez, J. O., Mattson, M. P. & de 
Cabo, R. 2007. Up-regulation of plasma membrane-associated redox activities in 
neuronal cells lacking functional mitochondria. Journal of Neurochemistry, 100, 
1364-1374. 
Jones, M. E. 1980. Pyrimidine Nucleotide Biosynthesis in Animals: Genes, 
Enzymers, and Regulation of UMP Biosynthesis. Annual Reviews of Biochemistry, 49, 
253-279. 
88 
 
Kagan, V. E., Serbinova, E. A. & Packer, L. 1990a. Generation and recycling of 
radicals from phenolic antioxidants. Archives of Biochemistry and Biophysics, 280, 
33-39. 
Kagan, V. E., Serbinova, E. A. & Packer, L. 1990b. Recycling and antioxidant 
activity of tocopherol homologs of differing hydrocarbon chain lengths in liver-
microsomes. Archives of Biochemistry and Biophysics, 282, 221-225. 
King, M. & Attardi, G. 1989. Human Cells Lacking mtDNA: Repopulation with 
Exogenous Mitochondria by Complementation. Science, 246, 500-503. 
Kirchhoff, S. R., Gupta, S. & Knowlton, A. A. 2002. Cytosolic heat shock protein 
60, apoptosis, and myocardial injury. Circulation, 105, 2899-2904. 
Klann, E., Roberson, E. D., Knapp, L. T. & Sweatt, J. D. 1998. A role for 
superoxide in protein kinase C activation and induction of long-term potentiation. 
Journal of Biological Chemistry, 273, 4516-4522. 
Lancaster, G. I. & Febbraio, M. A. 2005. Exosome-dependent Trafficking of 
HSP70: A NOVEL SECRETORY PATHWAY FOR CELLULAR STRESS 
PROTEINS. J. Biol. Chem., 280, 23349-23355. 
Larm, J. A., Vaillant, F., Linnane, A. W. & Lawen, A. 1994. Up-regulation of the 
plasma-membrane oxidoreductase as a prerequisite for the viability of human 
Namalwa RHO(0) cells. Journal of Biological Chemistry, 269, 30097-30100. 
Lewthwaite, J. C., Clarkin, C. E., Coates, A. R. M., Poole, S., Lawrence, R. A., 
Wheeler-Jones, C. P. D., Pitsillides, A. A., Singh, M. & Henderson, B. 2007. 
89 
 
Highly homologous Mycobacterium tuberculosis chaperonin 60 proteins with 
differential CD14 dependencies stimulate cytokine production by human monocytes 
through cooperative activation of p38 and ERK1/2 mitogen-activated protein kinases. 
International Immunopharmacology, 7, 230-240. 
Lin, K. M., Lin, B., Lian, I. Y., Mestril, R., Scheffler, I. E. & Dillmann, W. H. 
2001. Combined and individual mitochondrial HSP60 and HSP10 expression in 
cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths 
induced by simulated ischemia-reoxygenation. Circulation, 103, 1787-1792. 
Maguire, M., Coates, A. R. M. & Henderson, B. 2002a. Chaperonin 60 unfolds its 
secrets of cellular communication. Cell Stress Chaperones, 7, 317–329. 
Maguire, M., Coates, A. R. M. & Henderson, B. 2002b. Chaperonin 60 unfolds its 
secrets of cellular communication. Cell Stress & Chaperones, 7, 317-329. 
Mak, T. W. & Saunders, M. E. 2006. The Immune Response: Elsevier Inc. 
Martinus, R. D., Garth, G. P., Webster, T. L., Cartwright, P., Naylor, D. J., Hoj, 
P. B. & Hoogenraad, N. J. 1996. Selective induction of mitochondrial chaperones in 
response to loss of the mitochondrial genome. European Journal of Biochemistry, 
240, 98-103. 
Martinus, R. D., Linnane, A. W. & Nagley, P. 1993. Growth of RHO(0) human 
Namalwa cells lacking oxidative-phosphorylation can be sustained by redox 
compounds potassium ferricyanide or coenzyme q(10) putatively acting through the 
plasma-membrane oxidase. Biochemistry and Molecular Biology International, 31, 
997-1005. 
90 
 
Mattson, M. P. & Kroemer, G. 2003. Mitochondria in cell death: novel targets for 
neuroprotection and cardioprotection. Trends in Molecular Medicine, 9, 196-205. 
McCord, J. M. 2000. The evolution of free radicals and oxidative stress. American 
Journal of Medicine, 108, 652-659. 
Mills, K. I., Woodgate, L. J., Gilkes, A. F., Walsh, V., Sweeney, M. C., Brown, G. 
& Burnett, A. K. 1999. Inhibition of mitochondrial function in HL60 cells is 
associated with an increased apoptosis and expression of CD14. Biochemical and 
Biophysical Research Communications, 263, 294-300. 
Morais, R., Gregoire, M., Jeanotte, L. & Gravel, D. 1980. Chick Embryo Cells 
Rendered Respiratory-Deficient by Chloramphenicol and Ethidium Bromide are 
Auxothrophic for Pyrimidines. Biochemical and Biophysical Research 
Communications, 94, 71-77. 
Nagley, P., Sriprakash, K. S. & Linnane, A. W. 1977. In: Advances in Microbial 
Physiology (Ed. by Rose, A. H. & Tempest, D. W.), pp. 157-277. London: Acedamic 
Press. 
Nohl, H., Gille, L., Kozlov, A. & Staniek, K. 2003. Are mitochondria a spontaneous 
and permanent source of reactive oxygen species? Redox Report, 8, 135-141. 
Omar, B. A. & McCord, J. M. 1991. Interstitial equilibration of superoxide-
dismutase correlates with its protective effect in the isolated rabbit heart. Journal of 
Molecular and Cellular Cardiology, 23, 149-159. 
91 
 
Piskemik, C., Haindl, S., Behling, T., Gerald, Z., Kehrer, I., Redl, H. & Kozlov, 
A. V. 2008. Antimycin A and lipopolysaccharide cause the leakage of superoxide 
radicals from rat liver mitochondria. Biochimica Et Biophysica Acta-Molecular Basis 
of Disease, 1782, 280-285. 
Pockley, A. G. 2003. Heat shock proteins as regulators of the immune response. 
Lancet, 362, 469-476. 
Praeres da Costa, C. U. I., Wagner, H. & Miethke, T. C. 2003. Heat shock 
protein-mediated activation of innate immune cells. In: Heat shock protein and 
inflammation (Ed. by van Eden, W.), pp. 43-54. Basel, Switzerland: Birkhauser 
Verlag. 
Randord, J., Coates, A. & Henderson, B. 2000. Chaperonins are cell-signalling 
proteins: The Unfolding Biology of Molecular Chaperones. Expert Reviews, 15. 
Reddy, P. H. & Beal, M. F. 2005. Are mitochondria critical in the pathogenesis of 
Alzheimer's disease? Brain Research Reviews, 49, 618-632. 
Reed, J., Reed, T. A. & Hess, B. 1978. Circular-Dichroism Studies of the 
Cytochrome b-c1 Complex of Saccharomyces cerevisiae. European Journal of 
Biochemistry, 91, 255-261. 
Ritossa, F. A. 1962. A New Puffing Pattern Induced by Temperature Shock and DNP 
in Drosophilia. Experientia, 18, 571-573. 
Sambrook, J., Fritsch, E. F. & Maniatis, T. 1989. Extraction, Purification, and 
Analysis of Messenger RNA from Eukaryotic Cells. In: Molecular Cloning - A 
92 
 
Laboratory Manual (Ed. by Nolan, C.), pp. 7.3-7.84. New York: Cold Spring Harbor 
Laboratory Press. 
Sastre, J., Pallardo, F. V. & Vina, J. 2003. The role of mitochondrial oxidative 
stress in aging. Free Radical Biology and Medicine, 35, 1-8. 
Schwartz, M. & Cohen, I. R. 2000. Autoimmunity can benefit self-maintenance. 
Immunology Today, 21, 265-268. 
Slater, E. C. 1973. The Mechanism of Action of the Respiratory Inhibitor, 
Antimycin. Biochimica et Biophysica Acta, 301, 129-154. 
Thompson, B. Y., Sivam, G., Britigan, B. E., Rosen, G. M. & Cohen, M. S. 1988. 
Oxygen Metabolism of the HL-60 Cell Line: Comparison of the Effects of 
Monocytoid and Neutrophilic Differentiation. Journal of Leukocyte Biology, 43, 140-
147. 
Tissieres, A., Mitchell, H. K. & Tracey, U. 1974. Protein Synthesis in Salivary 
Glands of Drosophila melanogaster: Relation to Chromosome Puffs. Journal of 
Molecular Biology, 84, 389-398. 
Tse, H. M., Milton, M. J. & Piganelli, J. D. 2004. Mechanistic analysis of the 
immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: 
Implication for their use in targeting oxidation-reduction reactions in innate immunity. 
Free Radical Biology and Medicine, 36, 233-247. 
Tytell, M. & Hooper, P. L. 2001. Heat shock proteins: new keys to the development 
of cytoprotective therapies. Expert Opin Ther Targets., 5, 267-287. 
93 
 
Ueki, K., Tabeta, K., Yoshie, H. & Yamazaki, K. 2002. Self-heat shock protein 60 
induces tumour necrosis factor-alpha in monocyte-derived macrophage: possible role 
in chronic inflammatory periodontal disease. Clinical and Experimental Immunology, 
127, 72-77. 
Vaillant, F., Loveland, B. E., Nagley, P. & Linnane, A. W. 1991. Some 
biochemical-properties of human lymphoblastoid Namalwa cells grown anaerobically. 
Biochemistry International, 23, 571-580. 
Vaille, A., Jadot, G. & Elizagaray, A. 1990. Anti-inflammatory activity of various 
superoxide dismutases on polyarthritis in the Lewis rat. Biochemical Pharmacology, 
39, 247-255. 
Veereshwarayya, V., Kumar, P., Rosen, K. M., Mestril, R. & Querfurth, H. W. 
2006. Differential effects of mitochondrial heat shock protein 60 and related 
molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of 
complex IV and limit apoptosis. Journal of Biological Chemistry, 281, 29468-29478. 
Wallin, R. P. A., Lundqvist, A., More, S. H., von Bonin, A., Kiessling, R. & 
Ljunggren, H.-G. 2002. Heat-shock proteins as activators of the innate immune 
system. Trends in Immunology, 23, 130-135. 
Wikowski, J. & Zoller, M. 2001. Polymerase Chain Reaction. In: Recombinant DNA 
(Ed. by Watson, J. D. & Gilman, M.), pp. 79-98. New York: W.H. Freeman and 
Company. 
Yang, Q. W., Li, J. C., Lu, F. L., Wen, A. Q., Xiang, J., Zhang, L. L., Huang, Z. 
Y. & Wang, J. Z. 2008. Upregulated expression of toll-like receptor 4 in monocytes 
94 
 
correlates with severity of acute cerebral infarction. Journal of Cerebral Blood Flow 
and Metabolism, 28, 1588-1596. 
Zanin-Zhorov, A., Bruck, R., Tal, G., Oren, S., Aeed, H., Hershkoviz, R., Cohen, 
I. R. & Lider, O. 2005. Heat Shock Protein 60 Inhibits Th1-Mediated Hepatitis 
Model via Innate Regulation of Th1/Th2 Transcription Factors and Cytokines. J 
Immunol, 174, 3227-3236. 
Zhao, Y., Yokota, K., Ayada, K., Yamamoto, Y., Okada, T., Shen, L. & Oguma, 
K. 2007. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Toll-
like receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human 
monocytes. J Med Microbiol, 56, 154-164. 
Zhuang, J. G., Ren, Y., Snowden, R. T., Zhu, H. J., Gogvadze, V., Savill, J. S. & 
Cohen, G. M. 1998. Dissociation of phagocyte recognition of cells undergoing 
apoptosis from other features of the apoptotic program. Journal of Biological 
Chemistry, 273, 15628-15632. 
 
 
